XtalPi

XtalPi has raised $784 million in funding through multiple rounds: $400 million in Series D (August 11, 2021), $268 million in Post-IPO (February 27, 2025), and $ 116 million in Post-IPO (September 17, 2025). Key investors include Orbimed, 5Y Capital, HSG, Tencent, Renren, and SoftBank Vision Fund. XtalPi, headquartered in Cambridge, United States, develops AI-based drug discovery and development solutions. Its proprietary FACES system and ID4 platform leverage cloud computing and machine learning to predict crystal structures, identify polymorphs, and improve the efficiency and success rate of pharmaceutical R&D.